A Multi-centre, Single-arm, Open-label Study to Evaluate the Efficacy and Safety of Tenofovir Disoproxil Fumarate(TDF) Treatment in Chinese Chronic Hepatitis B (CHB) Subjects Following Failure of Multiple Nucleos(t)Ide Analogues(NAs)
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 19 Oct 2017
At a glance
- Drugs Tenofovir disoproxil fumarate (Primary)
- Indications Hepatitis B
- Focus Therapeutic Use
- Sponsors GlaxoSmithKline
- 13 Oct 2017 Planned End Date changed from 1 Aug 2018 to 4 Aug 2018.
- 13 Oct 2017 Planned primary completion date changed from 1 Aug 2018 to 4 Aug 2018.
- 03 Aug 2016 Status changed from recruiting to active, no longer recruiting.